Invested £6M to extend Centauri Therapeutics' Series A to £30M, supporting its lead clinical candidate.
Centauri Therapeutics is an immunotherapy company currently focused on infectious diseases and oncology
Centauri Therapeutics is an immunotherapy company currently focused on infectious diseases and oncology. Centauri’s approach to treating infectious diseases rests upon proprietary Alphamer® technology, which redirects naturally existing antibodies to treat life-threatening diseases.